Workflow
三星医疗:国内配用电龙头,出海提振增长
601567SANXING(601567) 西南证券·2025-01-03 00:18

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 40.81 CNY for the next six months [45]. Core Insights - The company is positioned as a leader in the domestic power distribution market, benefiting from the ongoing upgrade of smart grid infrastructure driven by distributed renewable energy integration [45][46]. - The overseas business is expanding, with significant orders expected in 2024, particularly in the distribution sector, indicating a shift from the consumption side to the distribution side [19][46]. - The medical segment is experiencing stable growth, with a projected compound annual growth rate (CAGR) of approximately 25% in the domestic rehabilitation medical market from 2020 to 2023 [16]. Summary by Sections Company Overview - The company operates in two main segments: smart power distribution and medical services, with a well-established international presence [61]. - It has a strong production and R&D capability globally, with manufacturing bases in Brazil, Indonesia, Poland, Germany, and Mexico, contributing to 17% of its revenue from overseas [61]. Domestic Power Distribution - The company secured a total of 760 million CNY in bids for smart meters in 2024, achieving a market share of 6.2% [15]. - It ranks first in market share for distribution transformers in both State Grid and Southern Grid, benefiting from the smart grid upgrade [15]. Overseas Business - The company has established five overseas production bases, enhancing its ability to meet demand and stabilize market share [19]. - In 2024, the company expects to receive orders worth 1.8 billion CNY from overseas markets, with a notable breakthrough in Europe and Mexico [19]. Medical Segment - The company has expanded its medical services by adding six hospitals in the first half of 2024, bringing the total to 34 hospitals [16]. - The CAGR for medical revenue from 2016 to 2023 is 24.4%, indicating robust growth potential [16]. Financial Forecast and Valuation - Revenue projections for 2024-2026 are 14.76 billion CNY, 17.98 billion CNY, and 21.31 billion CNY, respectively, with net profit growth rates of 22.6%, 25.4%, and 24.2% [46]. - The company is expected to achieve a net profit of 2.2 billion CNY from the power distribution segment and 600 million CNY from the medical segment by 2025 [46].